Abstract 211: Implications of the PEGASUS-TIMI 54 Trial for U.S. Clinical Practice [Session Title: Poster Session II]

Conclusions: In contemporary clinical practice, a minority of patients are on a P2Y12inhibitor beyond 1-year post-MI. Applying PEGASUS trial findings to clinical practice would result in a large increase in P2Y12 inhibitor use with a cost per ischemic event averted that is strongly influenced by the choice of therapy.

Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Bradley, S. M., Hess, G., Stewart, P., Armstrong, E., Farmer, S., Wasfy, J., Valle, J., Sandhu, A., Maddox, T. Tags: Session Title: Poster Session II Source Type: research